A Novel Methylation-based Model for Prognostic Prediction in Lung Adenocarcinoma
Contact us if these videos are not relevant.
Contact us if these videos are not relevant.
View abstract on PubMed
Summary
This summary is machine-generated.This study identified an eight-site DNA methylation signature to predict lung adenocarcinoma (LUAD) patient survival. This novel biomarker offers a promising tool for prognostic assessment in LUAD.
Area Of Science
- Oncology
- Molecular Biology
- Genetics
Background
- DNA methylation plays a role in lung adenocarcinoma (LUAD) development and diagnosis.
- The prognostic value of specific methylation sites in LUAD requires further investigation.
Purpose Of The Study
- To develop and validate a reliable methylation-based signature for predicting the overall survival of LUAD patients.
- To identify specific CpG sites that can serve as prognostic biomarkers for LUAD.
Main Methods
- Utilized DNA methylation and survival data from The Cancer Genome Atlas (TCGA) and Gene Expression Omnibus (GEO) datasets.
- Developed a prognostic signature using univariate least absolute shrinkage and selection operators (LASSO) and multivariate Cox regression models.
Main Results
- Identified and validated an eight-CpG site methylation signature as an optimal predictor of overall survival in LUAD.
- Demonstrated high predictive accuracy for the eight-site signature, especially when combined with clinical factors, via receiver operating characteristic (ROC) analysis.
Conclusions
- Successfully developed a novel eight-site methylation signature for predicting LUAD patient prognosis.
- This signature, derived from integrated bioinformatic analysis, holds potential for improving prognostic assessments in lung cancer.
Contact us if these videos are not relevant.
Contact us if these videos are not relevant.
